FibroGen, Inc.
FGEN
$0.2912
-$0.0269-8.46%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 233.34% | -48.98% | -44.20% | -42.67% | -66.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 233.34% | -48.98% | -44.20% | -42.67% | -66.74% |
| Cost of Revenue | -55.45% | -38.47% | -28.81% | -1.20% | -1.62% |
| Gross Profit | 109.89% | 26.76% | 17.48% | -27.34% | -55.94% |
| SG&A Expenses | -17.91% | -59.12% | -54.85% | -48.44% | -39.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.94% | -45.20% | -37.20% | -17.18% | -13.63% |
| Operating Income | 86.13% | 43.11% | 34.37% | 7.77% | -11.20% |
| Income Before Tax | 76.97% | 45.29% | 35.63% | 8.91% | -10.20% |
| Income Tax Expenses | 14.68% | -1,364.52% | -624.59% | -191.85% | -170.39% |
| Earnings from Continuing Operations | 77.02% | 45.43% | 35.74% | 9.10% | -9.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.26% | 58.60% | 47.76% | 21.71% | 3.21% |
| EBIT | 86.13% | 43.11% | 34.37% | 7.77% | -11.20% |
| EBITDA | 86.53% | 42.41% | 33.93% | 6.99% | -11.84% |
| EPS Basic | 83.58% | 59.90% | 49.71% | 25.17% | 6.83% |
| Normalized Basic EPS | 83.95% | 41.99% | 34.08% | 8.88% | -9.98% |
| EPS Diluted | 83.58% | 59.90% | 49.71% | 25.17% | 6.83% |
| Normalized Diluted EPS | 83.95% | 41.99% | 34.08% | 8.88% | -9.98% |
| Average Basic Shares Outstanding | 3.14% | 3.10% | 3.72% | 4.33% | 3.65% |
| Average Diluted Shares Outstanding | 3.14% | 3.10% | 3.72% | 4.33% | 3.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |